News

Filter

Current filters:

Anti-virals

1 to 9 of 750 results

National Institute of Allergy and Infectious Diseases launches ZMapp Ebola trial with Liberia

National Institute of Allergy and Infectious Diseases launches ZMapp Ebola trial with Liberia

02-03-2015

The USA’s National Institute of Allergy and Infectious Diseases has launched a clinical trial with…

Anti-viralsBiotechnologyLiberiaMapp BiopharmaceuticalResearchZMapp

NICE recommends Sovaldi and Olysio for hepatitis C

NICE recommends Sovaldi and Olysio for hepatitis C

25-02-2015

The UK’s National Institute for Health and Care Excellence (NICE) has published final guidance recommending…

Anti-viralsGilead SciencesJanssenOlysioPharmaceuticalRegulationSovaldiUK

Merck and Medicines Patent Pool sign licensing agreement for pediatric raltegravir

Merck and Medicines Patent Pool sign licensing agreement for pediatric raltegravir

24-02-2015

The Medicines Patent Pool has announced a license with US pharma giant Merck & Co for pediatric formulations…

Anti-viralsMerck & CoPharmaceuticalProductionRaltegravir Tablets

Mylan to distribute Sovaldi and Harvoni in India

23-02-2015

US generics major Mylan said today that its Indian subsidiary has entered into an agreement with Gilead…

Anti-viralsBiotechnologyGileadHarvoniIndiaMarkets & MarketingMylanSovaldi

Médecins du Monde challenges Gilead’s Sovaldi patent in EU

Médecins du Monde challenges Gilead’s Sovaldi patent in EU

11-02-2015

The high price of US biotech major Gilead Sciences’ blockbuster hepatitis C (HCV) drug Sovaldi (sofosbuvir)…

Anti-viralsEuropeGilead SciencesPharmaceuticalPricingSovaldi

IQWiG sees benefits for Triumeq and Eperzan

05-02-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) has announced its latest findings…

Anti-viralsDiabetesEperzanGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

Gilead beats 4th-qtr 2014 expectations, as hepatitis C drug sales soar

Gilead beats 4th-qtr 2014 expectations, as hepatitis C drug sales soar

04-02-2015

US biotech firm Gilead Sciences posted fourth-quarter and full-year financial results after markets closed…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldi

Chimerix to drop development of brincidofovir for Ebola

Chimerix to drop development of brincidofovir for Ebola

02-02-2015

US antiviral biopharma company Chimerix says that, after discussion with the US Food and Drug Administration,…

Anti-viralsBiotechnologybrincidofovirChimerixResearchTropical diseasesUSA

1 to 9 of 750 results

Back to top